1. Sweden In Vitro Diagnostics Market Outlook to 2018 - Clinical
Chemistry Genetic Testing, Haematology, Histology and
Cytology, Immuno Chemistry, Infectious Immunology and
Microbiology Culture
Report Details:
Published:December 2012
No. of Pages: 269
Price: Single User License – US$2500
Sweden In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Genetic Testing,
Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and
Microbiology Culture
Summary
GlobalData’s new report, “Sweden In Vitro Diagnostics Market Outlook to 2018 - Clinical
Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious
Immunology and Microbiology Culture” provides key market data on the Sweden In Vitro
Diagnostics market. The report provides value (USD million), volume (units) and average price
(USD) data for each segment and sub-segment within market categories – Immuno Chemistry,
Infectious Immunology, Clinical Chemistry, Haematology, Microbiology Culture, Histology And
Cytology and Genetic Testing. The report also provides company shares and distribution shares
data for each of the aforementioned market categories. The report is supplemented with global
corporate-level profiles of the key market participants with information on company financials and
pipeline products, wherever available.
This report is built using data and information sourced from proprietary databases, primary and
secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
- Market size and company share data for In Vitro Diagnostics market categories – Immuno
Chemistry, Infectious Immunology, Clinical Chemistry, Haematology, Microbiology Culture,
Histology And Cytology and Genetic Testing.
- Annualized market revenues (USD million), volume (units) and average price (USD) data for

2. each of the segments and sub-segments within market categories. Data from 2004 to 2011,
forecast forward for 7 years to 2018.
- 2011 company shares and distribution shares data for each of the market categories.
- Global corporate-level profiles of key companies operating within the Sweden In Vitro
Diagnostics market.
- Key players covered include F. Hoffmann-La Roche Ltd., Siemens Healthcare, Abbott
Laboratories, bioMerieux S.A., Ortho-Clinical Diagnostics Inc., Beckman Coulter, Inc. and others.
Reasons to buy
- Develop business strategies by identifying the key market categories and segments poised for
strong growth.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the Sweden In Vitro
Diagnostics competitive landscape.
- Develop capital investment strategies by identifying the key market segments expected to
register strong growth in the near future.
- What are the key distribution channels and what’s the most preferred mode of product
distribution – Identify, understand and capitalize.
Get your copy of this report @
http://www.reportsnreports.com/reports/213279-sweden-in-vitro-diagnostics-market-outlook-to-2018-clinical-
chemistry-genetic-testing-haematology-histology-and-cytology-immuno-chemistry-infectious-immunology-and-
microbiology-culture.html
Major points covered in Table of Contents of this report include
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 9
1.2 List of Figures 13
2 Introduction 16
2.1 What is This Report About? 16
3 In Vitro Diagnostics In Sweden 17
3.1 In Vitro Diagnostics, Market Segmentation 17
3.2 In Vitro Diagnostics, Sweden, Overall Revenue ($m), USD Constant, 2004-2018 18
3.3 In Vitro Diagnostics Market, Sweden, Revenue Mix ($m), 2011 20
3.4 In Vitro Diagnostics Market, Sweden, Category Contribution (%), 2011 21
3.5 In Vitro Diagnostics, Sweden, Company Share (2010-2011) 28
4 Clinical Chemistry In Sweden 30
4.1 Clinical Chemistry, Market Segmentation 30
4.2 Clinical Chemistry Market, Sweden, Revenue Mix ($m), 2011 31
4.3 Clinical Chemistry Market, Sweden, Segment Contribution (%), 2011 32
4.4 Clinical Chemistry Overall Revenue, (2004-2018) 33
4.4.1 Clinical Chemisty Analyzers, Revenue (2004-2018) 37

3. 4.4.2 Urine Analysis, Revenue (2004-2018) 41
4.5 Clinical Chemistry Distribution Share (2010-2011) 45
4.6 Clinical Chemistry, Sweden, Company Share (2010-2011) 46
5 Genetic Testing In Sweden 48
5.1 Genetic Testing, Market Segmentation 48
5.2 Genetic Testing Market, Sweden, Revenue Mix ($m), 2011 49
5.3 Genetic Testing Market, Sweden, Segment Contribution (%), 2011 50
5.4 Genetic Testing Overall Revenue, (2004-2018) 51
5.5 Genetic Testing Distribution Share (2010-2011) 55
5.6 Genetic Testing, Sweden, Company Share (2010-2011) 56
6 Haematology In Sweden 58
6.1 Haematology Market, Market Segmentation 58
6.2 Haematology Market, Sweden, Revenue Mix ($m), 2011 59
6.3 Haematology Market, Sweden, Segment Contribution (%), 2011 60
6.4 Haematology Overall Revenue, (2004-2018) 61
6.4.1 Haematology Reagents, Revenue (2004-2018) 65
6.4.2 Immunohaematology, Revenue (2004-2018) 69
6.4.3 Haemostasis, Revenue (2004-2018) 73
6.4.4 Haematology Rapid Tests, Revenue (2004-2018) 77
6.4.5 Haematology Cell Counters, Revenue (2004-2018) 81
6.5 Haematology Distribution Share (2010-2011) 85
6.6 Haematology, Sweden, Company Share (2010-2011) 86
7 Histology And Cytology In Sweden 88
7.1 Histology and Cytology Market, Market Segmentation 88
7.2 Histology And Cytology Market, Sweden, Revenue Mix ($m), 2011 89
7.3 Histology And Cytology Market, Sweden, Segment Contribution (%), 2011 90
7.4 Histology And Cytology Overall Revenue, (2004-2018) 91
7.5 Histology And Cytology Distribution Share (2010-2011) 95
7.6 Histology And Cytology, Sweden, Company Share (2010-2011) 96
8 Immuno Chemistry In Sweden 98
8.1 Immuno Chemistry Market, Sweden, Revenue Mix ($m), 2011 98
8.2 Immuno Chemistry Market, Sweden, Segment Contribution (%), 2011 99
8.3 Immuno Chemistry Overall Revenue, (2004-2018) 100
8.3.1 Disease Specific Immunochemistry, Revenue (2004-2018) 104
8.3.2 Drugs of Abuse / Toxicology, Revenue (2004-2018) 108
8.3.3 Endocrinology Tests, Revenue (2004-2018) 112
8.3.4 Immunochemistry Rapid Tests, Revenue (2004-2018) 116
8.3.5 Therapeutic Drug Monitoring, Revenue (2004-2018) 120
8.3.6 Immunochemistry Analyzers, Revenue (2004-2018) 124
8.4 Immuno Chemistry Distribution Share (2010-2011) 128
8.5 Immuno Chemistry, Sweden, Company Share (2010-2011) 129
9 Infectious Immunology In Sweden 131

4. 9.1 Infectious Immunology, Market Segmentation 131
9.2 Infectious Immunology Market, Sweden, Revenue Mix ($m), 2011 132
9.3 Infectious Immunology Market, Sweden, Segment Contribution (%), 2011 133
9.4 Infectious Immunology Overall Revenue, (2004-2018) 134
9.4.1 Infectious Immunology Rapid Tests, Revenue (2004-2018) 138
9.5 Infectious Immunology Distribution Share (2010-2011) 142
9.6 Infectious Immunology, Sweden, Company Share (2010-2011) 143
10 Microbiology Culture In Sweden 145
10.1 Microbiology Culture, Market Segmentation 145
10.2 Microbiology Culture Market, Sweden, Revenue Mix ($m), 2011 146
10.3 Microbiology Culture Market, Sweden, Segment Contribution (%), 2011 147
10.4 Microbiology Culture Overall Revenue, (2004-2018) 148
10.4.1 Microbiology Analyzers, Revenue (2004-2018) 152
10.5 Microbiology Culture Distribution Share (2010-2011) 156
10.6 Microbiology Culture, Sweden, Company Share (2010-2011) 157
11 Overview of Key Companies in Sweden In Vitro Diagnostics Market 159
11.1 F. Hoffmann-La Roche Ltd. 159
11.1.1 Company Overview 159
11.1.2 Share in the Sweden In Vitro Diagnostics Market 159
11.2 Siemens Healthcare 160
11.2.1 Company Overview 160
11.2.2 Share in the Sweden In Vitro Diagnostics Market 160
11.3 Abbott Laboratories 161
11.3.1 Company Overview 161
11.3.2 Share in the Sweden In Vitro Diagnostics Market 161
11.4 bioMerieux S.A. 162
11.4.1 Company Overview 162
11.4.2 Share in the Sweden In Vitro Diagnostics Market 162
11.5 Ortho-Clinical Diagnostics Inc. 163
11.5.1 Company Overview 163
11.5.2 Share in the Sweden In Vitro Diagnostics Market 163
11.6 Beckman Coulter, Inc. 164
11.6.1 Company Overview 164
11.6.2 Share in the Sweden In Vitro Diagnostics Market 164
11.7 Sysmex Corporation 165
11.7.1 Company Overview 165
11.8 Becton, Dickinson and Company 165
11.8.1 Company Overview 165
11.9 Bio-Rad Laboratories, Inc. 166
11.9.1 Company Overview 166
11.10 Qiagen N.V. 166
11.10.1 Company Overview 166

5. 11.11 DiaSorin S.p.A 167
11.11.1 Company Overview 167
11.12 Horiba, Ltd. 167
11.12.1 Company Overview 167
11.13 Diagnostica Stago, Inc. 168
11.13.1 Company Overview 168
11.14 PerkinElmer, Inc. 168
11.14.1 Company Overview 168
11.15 Thermo Fisher Scientific Inc. 169
11.15.1 Company Overview 169
11.16 Gen-Probe Incorporated 169
11.16.1 Company Overview 169
11.17 Grifols, S.A. 170
11.17.1 Company Overview 170
11.18 Cellestis Limited 170
11.18.1 Company Overview 170
11.19 Immucor, Inc. 171
11.19.1 Company Overview 171
11.20 Danaher Corporation 171
11.20.1 Company Overview 171
11.21 Mindray Medical International Limited 172
11.21.1 Company Overview 172
11.22 Life Technologies Corporation 172
11.22.1 Company Overview 172
11.23 Phadia AB 173
11.23.1 Company Overview 173
12 In Vitro Diagnostics Market Pipeline Products 174
12.1 Clinical Chemisty Market Pipeline Products 174
12.2 Immuno Chemistry Market Pipeline Products 178
12.3 Haematology Market Pipeline Products 189
12.4 Infectious Immunology Market Pipeline Products 191
12.5 Microbiology Culture Market Pipeline Products 198
12.6 Histology And Cytology Market Pipeline Products 199
12.7 Genetic Testing Market Pipeline Products 200
13 Financial Deals Landscape 205
13.1 Acquisition 205
13.1.1 Trinity Biotech To Acquire Fiomi Diagnostics From Alfven & Didrikson For $13.1 Million 205
13.1.2 Addtech Life Science Acquires Reagent And Instrument Firm, BioNordika Group 207
13.2 Partnerships 208
13.2.1 bioMerieux Enters Into Licensing Agreement With Quanterix For Simoa Technology 208
13.2.2 Affinity Biosensors Enters Into Distribution Agreement With Malvern Instruments For
Archimedes Particle Metrology System 210

6. 13.2.3 Agenix Enters Into Licensing Agreement With Tyrian Diagnostics For DiagnostIQ 211
13.2.4 BioDot Enters Into Co-Marketing Agreement With JOT Automation 212
13.2.5 BD Diagnostic Systems Enters Into Agreement With Lab21 To Develop New Oncology
Assays 213
13.2.6 Med BioGene Amends Licensing Agreement With Precision Therapeutics For LungExpress
Dx Test 214
13.2.7 Ovizio Imaging Systems Enters Into Distribution Agreement With Applikon Biotechnology
216
13.2.8 Life Technologies Enters Into Co-Marketing Agreement With Pathogenica 217
13.2.9 CML HealthCare Enters Into Agreement With MaRS Innovation 218
13.2.10 Akrivis Technologies Enters Into Co-Development Agreement With United States
Biological 219
13.2.11 Castle Biosciences Enters Into Licensing Agreement With Brigham and Women''s Hospital
For Mesothelioma Test 220
13.2.12 Scienion Enters Into Co-Marketing Agreement With Maine Manufacturing For Protein
Array Products 221
13.2.13 GeneCentric Diagnostics Enters Into Licensing Agreement With University of North
Carolina 222
13.2.14 Epistem Enters Into Distribution Agreement With Becton Dickinson For Mycobacterium TB
Test 223
13.2.15 SciFluor Life Sciences Enters Into Distribution Agreement With Sigma-Aldrich For
PhenoFluor 224
13.2.16 Immuno-Biological Labs Enters Into Licensing Agreement With IBL International 225
13.2.17 MDxHealth Enters Into Licensing Agreement With Merck For MGMT Diagnostic Test 226
13.2.18 NicOx Enters Into Licensing Agreement With Rapid Pathogen Screening For AdenoPlus
228
13.2.19 Immunexpress Enters Into Licensing Agreement With Debiopharm And Biocartis 230
13.2.20 Omega Diagnostics Enters Into Licensing Agreement With Burnet Institute For CD4 POC
Test 232
13.2.21 One Lambda Enters Into Co-Marketing Agreement With CellTrend 233
13.2.22 Clarient Diagnostic Services Enters Into Licensing Agreement With Insight Genetics For
ALK Cancer Biomarker 234
13.2.23 Affymetrix Enters Into Technology Integration Agreement With Leica Microsystems 235
13.2.24 Biohit Enters Into Distribution Agreement With Euro-Diagnostica For GastroPanel 236
13.2.25 Ventana Medical Enters Into Licensing Agreement With Gen-Probe For IP Of ERG Marker
237
13.2.26 Affymetrix Enters Into Distribution Agreement With ScreenCell For Circulating Tumor Cell
Technology 238
13.2.27 Hycor Biomedical Enters Into Distribution Agreement With Roche For KOVA 239
13.2.28 Opko Health Enters Into Licensing Agreement With International Health Technology For
Prostate Cancer Biomarker Panel 240
13.2.29 ZyGem Enters Into Co-Marketing Agreement With Tataa Biocenter 241

7. 13.2.30 Genome Diagnostics Enters Into Co-Marketing Agreement With Qiagen For LongRange
PCR Kit 242
13.2.31 Denator Enters Into Co-Development Agreement With Erasmus And Amsterdam Medical
For Cancer Biomarker Platform 243
13.2.32 Biofortuna Extends Co-Marketing Agreement With Abbott Labs For SSPGo 244
13.2.33 Pressure BioSciences Enters Into Licensing Agreement With Target Discovery For
Pressure Cycling Technology 245
13.2.34 LipoScience Enters Into Licensing Agreement With Cleveland Clinic 247
13.2.35 GE Healthcare Enters Into Co-Development Agreement With NXT2B For Compact
Cyclotron And PET Tracer System 248
13.2.36 NexDx Enters Into Licensing Agreement With University of California For Epigenetic
Biomarkers 249
13.2.37 Bio-Rad Labs Extends Distribution Agreement With Luminex For MAGPIX 250
13.2.38 Thermo Fisher Scientific Enters Into Distribution Agreement With Abbott For PCT Assay
For Sepsis 251
14 Recent Developments 252
14.1 Government and Public Interest 252
14.1.1 May 07, 2012: Researchers Of University of Gothenburg Develops Biomarkers That Can
Reveal IBS 252
14.2 Product News 252
14.2.1 Jun 08, 2012: Allenex: University of Miami Initiates Clinical Trial Of XM-ONE 252
14.2.2 Mar 08, 2012: Hansa Medical Announces Issuance Of European Patent For Diagnostic
Method HMD-301 253
15 Appendix 254
15.1 Definitions of Markets Covered in the Report 255
15.1.1 In Vitro Diagnostics 255
15.2 Research Methodology 266
15.3 Secondary Research 266
15.4 Primary Research 267
15.5 Models 267
15.6 Forecasts 268
15.7 Expert Panels 268
15.8 GlobalData Consulting 268
15.9 Currency Conversion 269
15.10 Contact Us 269
15.11 Disclaimer 269
1.1 List of Tables
Table 1: In Vitro Diagnostics, Sweden, Overall Revenue ($m), USD Constant, 2004-2018 19
Table 2: In Vitro Diagnostics Market, Sweden, Category Contribution (%), 2011 21
Table 3: In Vitro Diagnostics Market, Sweden, Cross-Category Analysis, 2004-2018 23
Table 4: In Vitro Diagnostics, Sweden, Overall Revenue ($m), USD Constant, Historic, 2004-2011

8. 25
Table 5: In Vitro Diagnostics, Sweden, Overall Revenue ($m), USD Constant, Forecast, 2011-
2018 27
Table 6: In Vitro Diagnostics, Sweden, Company Share by Revenue ($m), USD Constant, 2010-
2011 29
Table 7: Clinical Chemistry Market, Sweden, Segment Contribution (%), 2011 32
Table 8: Clinical Chemistry, Sweden, Revenue ($m) USD Constant, by Segment, Historic, 2004-
2011 34
Table 9: Clinical Chemistry, Sweden, Revenue ($m) USD Constant, by Segment, Forecast, 2011-
2018 36
Table 10: Clinical Chemisty Analyzers, Sweden, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 38
Table 11: Clinical Chemisty Analyzers, Sweden, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 40
Table 12: Urine Analysis, Sweden, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-
2011 42
Table 13: Urine Analysis, Sweden, Revenue ($m) USD Constant, by Sub-Segment, Forecast,
2011-2018 44
Table 14: Clinical Chemistry, Sweden, Distribution Share by Revenue ($m), USD Constant, 2010-
2011 45
Table 15: Clinical Chemistry, Sweden, Company Share by Revenue ($m), USD Constant, 2010-
2011 47
Table 16: Genetic Testing Market, Sweden, Segment Contribution (%), 2011 50
Table 17: Genetic Testing, Sweden, Revenue ($m) USD Constant, by Segment, Historic, 2004-
2011 52
Table 18: Genetic Testing, Sweden, Revenue ($m) USD Constant, by Segment, Forecast, 2011-
2018 54
Table 19: Genetic Testing, Sweden, Distribution Share by Revenue ($m), USD Constant, 2010-
2011 55
Table 20: Genetic Testing, Sweden, Company Share by Revenue ($m), USD Constant, 2010-
2011 57
Table 21: Haematology Market, Sweden, Segment Contribution (%), 2011 60
Table 22: Haematology, Sweden, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
62
Table 23: Haematology, Sweden, Revenue ($m) USD Constant, by Segment, Forecast, 2011-
2018 64
Table 24: Haematology Reagents, Sweden, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 66
Table 25: Haematology Reagents, Sweden, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 68
Table 26: Immunohaematology, Sweden, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 70

9. Table 27: Immunohaematology, Sweden, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 72
Table 28: Haemostasis, Sweden, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-
2011 74
Table 29: Haemostasis, Sweden, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-
2018 76
Table 30: Haematology Rapid Tests, Sweden, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 78
Table 31: Haematology Rapid Tests, Sweden, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 80
Table 32: Haematology Cell Counters, Sweden, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 82
Table 33: Haematology Cell Counters, Sweden, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 84
Table 34: Haematology, Sweden, Distribution Share by Revenue ($m), USD Constant, 2010-2011
85
Table 35: Haematology, Sweden, Company Share by Revenue ($m), USD Constant, 2010-2011
87
Table 36: Histology And Cytology Market, Sweden, Segment Contribution (%), 2011 90
Table 37: Histology And Cytology, Sweden, Revenue ($m) USD Constant, by Segment, Historic,
2004-2011 92
Table 38: Histology And Cytology, Sweden, Revenue ($m) USD Constant, by Segment, Forecast,
2011-2018 94
Table 39: Histology And Cytology, Sweden, Distribution Share by Revenue ($m), USD Constant,
2010-2011 95
Table 40: Histology And Cytology, Sweden, Company Share by Revenue ($m), USD Constant,
2010-2011 97
Table 41: Immuno Chemistry Market, Sweden, Segment Contribution (%), 2011 99
Table 42: Immuno Chemistry, Sweden, Revenue ($m) USD Constant, by Segment, Historic, 2004-
2011 101
Table 43: Immuno Chemistry, Sweden, Revenue ($m) USD Constant, by Segment, Forecast,
2011-2018 103
Table 44: Disease Specific Immunochemistry, Sweden, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 105
Table 45: Disease Specific Immunochemistry, Sweden, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 107
Table 46: Drugs of Abuse / Toxicology, Sweden, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 109
Table 47: Drugs of Abuse / Toxicology, Sweden, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 111
Table 48: Endocrinology Tests, Sweden, Revenue ($m) USD Constant, by Sub-Segment, Historic,
2004-2011 113

10. Table 49: Endocrinology Tests, Sweden, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 115
Table 50: Immunochemistry Rapid Tests, Sweden, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 117
Table 51: Immunochemistry Rapid Tests, Sweden, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 119
Table 52: Therapeutic Drug Monitoring, Sweden, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 121
Table 53: Therapeutic Drug Monitoring, Sweden, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 123
Table 54: Immunochemistry Analyzers, Sweden, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 125
Table 55: Immunochemistry Analyzers, Sweden, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 127
Table 56: Immuno Chemistry, Sweden, Distribution Share by Revenue ($m), USD Constant, 2010-
2011 128
Table 57: Immuno Chemistry, Sweden, Company Share by Revenue ($m), USD Constant, 2010-
2011 130
Table 58: Infectious Immunology Market, Sweden, Segment Contribution (%), 2011 133
Table 59: Infectious Immunology, Sweden, Revenue ($m) USD Constant, by Segment, Historic,
2004-2011 135
Table 60: Infectious Immunology, Sweden, Revenue ($m) USD Constant, by Segment, Forecast,
2011-2018 137
Table 61: Infectious Immunology Rapid Tests, Sweden, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 139
Table 62: Infectious Immunology Rapid Tests, Sweden, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 141
Table 63: Infectious Immunology, Sweden, Distribution Share by Revenue ($m), USD Constant,
2010-2011 142
Table 64: Infectious Immunology, Sweden, Company Share by Revenue ($m), USD Constant,
2010-2011 144
Table 65: Microbiology Culture Market, Sweden, Segment Contribution (%), 2011 147
Table 66: Microbiology Culture, Sweden, Revenue ($m) USD Constant, by Segment, Historic,
2004-2011 149
Table 67: Microbiology Culture, Sweden, Revenue ($m) USD Constant, by Segment, Forecast,
2011-2018 151
Table 68: Microbiology Analyzers, Sweden, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 153
Table 69: Microbiology Analyzers, Sweden, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 155
Table 70: Microbiology Culture, Sweden, Distribution Share by Revenue ($m), USD Constant,
2010-2011 156

11. Table 71: Microbiology Culture, Sweden, Company Share by Revenue ($m), USD Constant, 2010-
2011 158
Table 72: Clinical Chemisty Market Pipeline Products 174
Table 73: Immuno Chemistry Market Pipeline Products 178
Table 74: Haematology Market Pipeline Products 189
Table 75: Infectious Immunology Market Pipeline Products 191
Table 76: Microbiology Culture Market Pipeline Products 198
Table 77: Histology And Cytology Market Pipeline Products 199
Table 78: Genetic Testing Market Pipeline Products 200
Table 79: Trinity Biotech To Acquire Fiomi Diagnostics From Alfven & Didrikson For $13.1 Million
205
Table 80: Addtech Life Science Acquires Reagent And Instrument Firm, BioNordika Group 207
Table 81: bioMerieux Enters Into Licensing Agreement With Quanterix For Simoa Technology 208
Table 82: Affinity Biosensors Enters Into Distribution Agreement With Malvern Instruments For
Archimedes Particle Metrology System 210
Table 83: Agenix Enters Into Licensing Agreement With Tyrian Diagnostics For DiagnostIQ 211
Table 84: BioDot Enters Into Co-Marketing Agreement With JOT Automation 212
Table 85: BD Diagnostic Systems Enters Into Agreement With Lab21 To Develop New Oncology
Assays 213
Table 86: Med BioGene Amends Licensing Agreement With Precision Therapeutics For
LungExpress Dx Test 214
Table 87: Ovizio Imaging Systems Enters Into Distribution Agreement With Applikon
Biotechnology 216
Table 88: Life Technologies Enters Into Co-Marketing Agreement With Pathogenica 217
Table 89: CML HealthCare Enters Into Agreement With MaRS Innovation 218
Table 90: Akrivis Technologies Enters Into Co-Development Agreement With United States
Biological 219
Table 91: Castle Biosciences Enters Into Licensing Agreement With Brigham and Women''s
Hospital For Mesothelioma Test 220
Table 92: Scienion Enters Into Co-Marketing Agreement With Maine Manufacturing For Protein
Array Products 221
Table 93: GeneCentric Diagnostics Enters Into Licensing Agreement With University of North
Carolina 222
Table 94: Epistem Enters Into Distribution Agreement With Becton Dickinson For Mycobacterium
TB Test 223
Table 95: SciFluor Life Sciences Enters Into Distribution Agreement With Sigma-Aldrich For
PhenoFluor 224
Table 96: Immuno-Biological Labs Enters Into Licensing Agreement With IBL International 225
Table 97: MDxHealth Enters Into Licensing Agreement With Merck For MGMT Diagnostic Test
226
Table 98: NicOx Enters Into Licensing Agreement With Rapid Pathogen Screening For AdenoPlus
228

12. Table 99: Immunexpress Enters Into Licensing Agreement With Debiopharm And Biocartis 230
Table 100: Omega Diagnostics Enters Into Licensing Agreement With Burnet Institute For CD4
POC Test 232
Table 101: One Lambda Enters Into Co-Marketing Agreement With CellTrend 233
Table 102: Clarient Diagnostic Services Enters Into Licensing Agreement With Insight Genetics
For ALK Cancer Biomarker 234
Table 103: Affymetrix Enters Into Technology Integration Agreement With Leica Microsystems 235
Table 104: Biohit Enters Into Distribution Agreement With Euro-Diagnostica For GastroPanel 236
Table 105: Ventana Medical Enters Into Licensing Agreement With Gen-Probe For IP Of ERG
Marker 237
Table 106: Affymetrix Enters Into Distribution Agreement With ScreenCell For Circulating Tumor
Cell Technology 238
Table 107: Hycor Biomedical Enters Into Distribution Agreement With Roche For KOVA 239
Table 108: Opko Health Enters Into Licensing Agreement With International Health Technology
For Prostate Cancer Biomarker Panel 240
Table 109: ZyGem Enters Into Co-Marketing Agreement With Tataa Biocenter 241
Table 110: Genome Diagnostics Enters Into Co-Marketing Agreement With Qiagen For
LongRange PCR Kit 242
Table 111: Denator Enters Into Co-Development Agreement With Erasmus And Amsterdam
Medical For Cancer Biomarker Platform 243
Table 112: Biofortuna Extends Co-Marketing Agreement With Abbott Labs For SSPGo 244
Table 113: Pressure BioSciences Enters Into Licensing Agreement With Target Discovery For
Pressure Cycling Technology 245
Table 114: LipoScience Enters Into Licensing Agreement With Cleveland Clinic 247
Table 115: GE Healthcare Enters Into Co-Development Agreement With NXT2B For Compact
Cyclotron And PET Tracer System 248
Table 116: NexDx Enters Into Licensing Agreement With University of California For Epigenetic
Biomarkers 249
Table 117: Bio-Rad Labs Extends Distribution Agreement With Luminex For MAGPIX 250
Table 118: Thermo Fisher Scientific Enters Into Distribution Agreement With Abbott For PCT
Assay For Sepsis 251
1.2 List of Figures
Figure 1: In Vitro Diagnostics, Market Segmentation 17
Figure 2: In Vitro Diagnostics, Sweden, Overall Revenue ($m), USD Constant, 2004-2018 18
Figure 3: In Vitro Diagnostics Market, Sweden, Revenue Mix ($m), 2011 20
Figure 4: In Vitro Diagnostics Market, Sweden, Category Contribution (%), 2011 21
Figure 5: In Vitro Diagnostics Market, Sweden, Cross-Category Analysis, 2004-2018 22
Figure 6: In Vitro Diagnostics, Sweden, Overall Revenue ($m), USD Constant, Historic, 2004-2011
24
Figure 7: In Vitro Diagnostics, Sweden, Overall Revenue ($m), USD Constant, Forecast, 2011-
2018 26

13. Figure 8: In Vitro Diagnostics, Sweden, Company Share (%), 2011 28
Figure 9: Clinical Chemistry, Market Segmentation 30
Figure 10: Clinical Chemistry Market, Sweden, Revenue Mix ($m), 2011 31
Figure 11: Clinical Chemistry Market, Sweden, Segment Contribution (%), 2011 32
Figure 12: Clinical Chemistry, Sweden, Revenue ($m) USD Constant, by Segment, Historic, 2004-
2011 33
Figure 13: Clinical Chemistry, Sweden, Revenue ($m) USD Constant, by Segment, Forecast,
2011-2018 35
Figure 14: Clinical Chemisty Analyzers, Sweden, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 37
Figure 15: Clinical Chemisty Analyzers, Sweden, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 39
Figure 16: Urine Analysis, Sweden, Revenue ($m) USD Constant, by Sub-Segment, Historic,
2004-2011 41
Figure 17: Urine Analysis, Sweden, Revenue ($m) USD Constant, by Sub-Segment, Forecast,
2011-2018 43
Figure 18: Clinical Chemistry, Sweden, Company Share (%), 2011 46
Figure 19: Genetic Testing, Market Segmentation 48
Figure 20: Genetic Testing Market, Sweden, Revenue Mix ($m), 2011 49
Figure 21: Genetic Testing Market, Sweden, Segment Contribution (%), 2011 50
Figure 22: Genetic Testing, Sweden, Revenue ($m) USD Constant, by Segment, Historic, 2004-
2011 51
Figure 23: Genetic Testing, Sweden, Revenue ($m) USD Constant, by Segment, Forecast, 2011-
2018 53
Figure 24: Genetic Testing, Sweden, Company Share (%), 2011 56
Figure 25: Haematology Market, Market Segmentation 58
Figure 26: Haematology Market, Sweden, Revenue Mix ($m), 2011 59
Figure 27: Haematology Market, Sweden, Segment Contribution (%), 2011 60
Figure 28: Haematology, Sweden, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
61
Figure 29: Haematology, Sweden, Revenue ($m) USD Constant, by Segment, Forecast, 2011-
2018 63
Figure 30: Haematology Reagents, Sweden, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 65
Figure 31: Haematology Reagents, Sweden, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 67
Figure 32: Immunohaematology, Sweden, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 69
Figure 33: Immunohaematology, Sweden, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 71
Figure 34: Haemostasis, Sweden, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-
2011 73

14. Figure 35: Haemostasis, Sweden, Revenue ($m) USD Constant, by Sub-Segment, Forecast,
2011-2018 75
Figure 36: Haematology Rapid Tests, Sweden, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 77
Figure 37: Haematology Rapid Tests, Sweden, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 79
Figure 38: Haematology Cell Counters, Sweden, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 81
Figure 39: Haematology Cell Counters, Sweden, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 83
Figure 40: Haematology, Sweden, Company Share (%), 2011 86
Figure 41: Histology and Cytology Market, Market Segmentation 88
Figure 42: Histology And Cytology Market, Sweden, Revenue Mix ($m), 2011 89
Figure 43: Histology And Cytology Market, Sweden, Segment Contribution (%), 2011 90
Figure 44: Histology And Cytology, Sweden, Revenue ($m) USD Constant, by Segment, Historic,
2004-2011 91
Figure 45: Histology And Cytology, Sweden, Revenue ($m) USD Constant, by Segment, Forecast,
2011-2018 93
Figure 46: Histology And Cytology, Sweden, Company Share (%), 2011 96
Figure 47: Immuno Chemistry Market, Sweden, Revenue Mix ($m), 2011 98
Figure 48: Immuno Chemistry Market, Sweden, Segment Contribution (%), 2011 99
Figure 49: Immuno Chemistry, Sweden, Revenue ($m) USD Constant, by Segment, Historic,
2004-2011 100
Figure 50: Immuno Chemistry, Sweden, Revenue ($m) USD Constant, by Segment, Forecast,
2011-2018 102
Figure 51: Disease Specific Immunochemistry, Sweden, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 104
Figure 52: Disease Specific Immunochemistry, Sweden, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 106
Figure 53: Drugs of Abuse / Toxicology, Sweden, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 108
Figure 54: Drugs of Abuse / Toxicology, Sweden, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 110
Figure 55: Endocrinology Tests, Sweden, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 112
Figure 56: Endocrinology Tests, Sweden, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 114
Figure 57: Immunochemistry Rapid Tests, Sweden, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 116
Figure 58: Immunochemistry Rapid Tests, Sweden, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 118
Figure 59: Therapeutic Drug Monitoring, Sweden, Revenue ($m) USD Constant, by Sub-Segment,

15. Historic, 2004-2011 120
Figure 60: Therapeutic Drug Monitoring, Sweden, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 122
Figure 61: Immunochemistry Analyzers, Sweden, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 124
Figure 62: Immunochemistry Analyzers, Sweden, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 126
Figure 63: Immuno Chemistry, Sweden, Company Share (%), 2011 129
Figure 64: Infectious Immunology, Market Segmentation 131
Figure 65: Infectious Immunology Market, Sweden, Revenue Mix ($m), 2011 132
Figure 66: Infectious Immunology Market, Sweden, Segment Contribution (%), 2011 133
Figure 67: Infectious Immunology, Sweden, Revenue ($m) USD Constant, by Segment, Historic,
2004-2011 134
Figure 68: Infectious Immunology, Sweden, Revenue ($m) USD Constant, by Segment, Forecast,
2011-2018 136
Figure 69: Infectious Immunology Rapid Tests, Sweden, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 138
Figure 70: Infectious Immunology Rapid Tests, Sweden, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 140
Figure 71: Infectious Immunology, Sweden, Company Share (%), 2011 143
Figure 72: Microbiology Culture, Market Segmentation 145
Figure 73: Microbiology Culture Market, Sweden, Revenue Mix ($m), 2011 146
Figure 74: Microbiology Culture Market, Sweden, Segment Contribution (%), 2011 147
Figure 75: Microbiology Culture, Sweden, Revenue ($m) USD Constant, by Segment, Historic,
2004-2011 148
Figure 76: Microbiology Culture, Sweden, Revenue ($m) USD Constant, by Segment, Forecast,
2011-2018 150
Figure 77: Microbiology Analyzers, Sweden, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 152
Figure 78: Microbiology Analyzers, Sweden, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 154
Figure 79: Microbiology Culture, Sweden, Company Share (%), 2011 157
Figure 80: F. Hoffmann-La Roche Ltd., Company Share (%),Sweden In Vitro Diagnostics Market,
2011 159
Figure 81: Siemens Healthcare, Company Share (%),Sweden In Vitro Diagnostics Market, 2011
160
Figure 82: Abbott Laboratories, Company Share (%),Sweden In Vitro Diagnostics Market, 2011
161
Figure 83: bioMerieux S.A., Company Share (%),Sweden In Vitro Diagnostics Market, 2011 162
Figure 84: Ortho-Clinical Diagnostics Inc., Company Share (%),Sweden In Vitro Diagnostics
Market, 2011 163
Figure 85: Beckman Coulter, Inc., Company Share (%),Sweden In Vitro Diagnostics Market, 2011

16. 164
Contact: sales@reportsandreports.com for more information.